Optitrop-Lung05 is a hit, as promised, and then some.

Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.

First human data for BeOne’s BGB-B2033 lack the wow factor.

Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.

First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.

Golcadomide and iberdomide are set to feature at EHA.

Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.

Rival BTK degraders face off in CLL patients naive to BTK inhibition.

The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.